Business
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure b
About this update from Sinopharm Group Co., Ltd. Class H
[{"type":"text","content":"BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure broad, non-exclusionary public dissemination of this information.","length":647,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FWTD.3pJkIGaULeVJR4ImQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMQ--/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/FWTD.3pJkIGaULeVJR4ImQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMQ--/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The NDA establishes a formal framework for Woori IO and Sinopharm to exchange confidential information relating to Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties to evaluate potential regulatory, clinical, and commercial pathways in China. Sinopharm Group, with reported 2024 revenue of approximately USD 81 billion, is generally considered China's largest pharmaceutical and medical device distributor with the most extensive nationwide network.","length":503,"tagName":"p"},{"type":"text","content":"China represents one of the world's largest and fastest-growing diabetes markets, with more than 140 million people estimated to be living with the disease and rising demand for convenient glucose monitoring solution...